Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEODOC: XP-DC Vaccine in Ovarian Cancer
NCT05773859Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in epithelial ovarian cancer (EOC), sponsored by Radboud University Medical Center. Primary endpoint: Number of patients with an immunological response to XP-DC vaccination at 10 weeks. Started Mar 2023; status: recruiting.
02
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT05773859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05773859.